Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 488-492

  Edler, David ^a,c   Kressner, Ulf ^b   Ragnhammar, Peter ^c   Johnston, Patrick G ^d   Magnusson, Inger ^a   Glimelius, Bengt ^b   Påhlman, Lars ^b   Lindmark, Gudrun ^e   Blomgren, Henric ^c  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

EID: 0033981858     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jass, J. R., Atkin, W. S., Cuzick, J., Bussey, H. J. R., Morson, B. C., Northover, J. M. A., and Todd, I. P. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology, 10: 437-459, 1986.
2. Lindmark, G., Bergström, R., Påhlman, L., and Glimelius, B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br. J. Cancer, 71: 1090-1094, 1995.
3. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587-597, 1992.
4. Harris, A. L. Mutant p53 - the commonest genetic abnormality in human cancer? J. Pathol., 162: 5-6, 1990.
5. Chang, F., Syrjanen, S., and Syrjanen, K. Implications of the p53 tumor suppressor gene in clinical oncology. J. Clin. Oncol., 4: 1009-1022, 1995.
6. Levine, A. J., Momand, J., and Finlay, C. The p53 tumor suppressor gene. Nature (Lond.), 351: 453-456, 1992.
7. McLeod, H. L., and Murray, G. I. Tumour markers of prognosis in colorectal cancer. Br. J. Cancer, 79: 191-203, 1999.
8. Danenberg, P. V. Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim. Biophys. Acta, 473: 73-92, 1977.
9. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
10. Lenz, H. J., Hayashi, K., Salonga, D., Danenberg, K. D., Danenberg, P. V., Metzger, R., Banerjee, D., Bertino, S. G., Leichman, L. P., and Leichman, C. G. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res., 4: 1243-1250, 1998.
11. Lenz, H. J., Danenberg, K. D., Leichman, C. G., Florentine, B., Johnston, P. G., Groshen, S., Zhou, L., Xiong, Y. P., Danenberg, P. V., and Leichman, L. P. p53 and thymidylate synthase expression in untreated stage II colon cancer: association with recurrence, survival, and site. Clin. Cancer Res., 4: 1227-1234, 1998.
12. Yamachika, T., Nakanishi, H., Inada, K., Tsukamoto, T., Kato, T., Fukushima, M., Inoue, M., and Tatematsu, M. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer (Phila.), 82: 70-77, 1998.
13. Johnston, P. G., Lenz, H. J., Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V., and Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 55: 1407-1412, 1995.
14. Leichman, L., Lenz, H. J., Leichman, C. G., Groshen, S., Danenberg, K. D., Baranda, J., Spears, C. P., Boswell, W., Silberman, H., Ortega, A., Stain, S., Beart, R., and Danenberg, P. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur. J. Cancer, 7/8: 1306-1310, 1995.
15. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 151: 237-244, 1992.
16. Johnston, P. G., Liang, C. M., Henry, S., Chabner, B. A., and Allegra, C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res., 51: 6668-6676, 1991.
17. Kressner, U., Lindmark, G., Gerdin, B., Påhlman, L., and Glimelius, B. Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res., 16: 951-958, 1996.
18. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
19. Gehan, E. A. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika, 52: 203-223, 1965.
20. Cox, D. R. Regression models and life-tables. J. R. Statist. Soc. Ser. B, 34: 187-220, 1972.
21. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
22. Edler, D., Blomgren, H., Allegra, C. J., Johnston, P. G., Lagerstedt, U., Magnusson, I., and Ragnhammar, P. Immunohistochemical determination of thymidylate synthase in colorectal cancer-methodological studies. Eur. J. Cancer, 33: 13, 2278-2281, 1997.
23. Kerr, D. J. Clinical efficacy of "Tomudex" (raltitrexed) in advanced colorectal cancer. Anticancer Drugs, 8 (Suppl. 2): 11-15, 1997.
24. Blackledge, G. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ("Tomudex"). Br. J. Cancer, 77 (Suppl. 2): 29-37, 1998.
25. Findlay, M. P. N., Cunningham, D., Morgan, G., Clinton, S., Hardcastle, A., and Aherne, G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br. J. Cancer. 75: 903-909, 1997.